Avid Bioservices (CDMO) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Avid Bioservices (CDMO) PT Raised to $11 at H.C. Wainwright
September 11, 2018 7:12 AM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Avid Bioservices (NASDAQ: CDMO) to $11.00 (from $6.00) while maintaining a Buy rating.
Pantginis commented, "Yesterday, CDMO reported F1Q19 results, posting EPS of ($0.06), compared with our estimate of ($0.01) and consensus of ($0.13). Revenue for the first quarter was $12.58 million compared with our estimate of $12.87 million and consensus of $8.96 million. Avid ended the quarter with $37.5 million in cash. Management reaffirmed its F2019 revenue guidance of $51-55 million. Under... More
